These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9631992)

  • 1. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.
    Rich P; Scher RK; Breneman D; Savin RC; Feingold DS; Konnikov N; Shupack JL; Pinnell S; Levine N; Lowe NJ; Aly R; Odom RB; Greer DL; Morman MR; Bucko AD; Tschen EH; Elewski BE; Smith EB; Hilbert J
    J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S103-9. PubMed ID: 9631992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.
    Savin RC; Drake L; Babel D; Stewart DM; Rich P; Ling MR; Breneman D; Scher RK; Martin AG; Pariser DM; Pariser RJ; Ellis CN; Kang S; Friedman D; Katz HI; McDonald CJ; Muglia J; Webster G; Elewski BE; Leyden JJ; Bucko AD; Tschen EH; Hanifin JM; Morman MR; Hilbert J
    J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S110-6. PubMed ID: 9631993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.
    Scher RK; Breneman D; Rich P; Savin RC; Feingold DS; Konnikov N; Shupack JL; Pinnell S; Levine N; Lowe NJ; Aly R; Odom RB; Greer DL; Morman MR; Bucko AD; Tschen EH; Elewski BE; Smith EB
    J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S77-86. PubMed ID: 9631989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.
    Ling MR; Swinyer LJ; Jarratt MT; Falo L; Monroe EW; Tharp M; Kalivas J; Weinstein GD; Asarch RG; Drake L; Martin AG; Leyden JJ; Cook J; Pariser DM; Pariser R; Thiers BH; Lebwohl MG; Babel D; Stewart DM; Eaglstein WH; Falanga V; Katz HI; Bergfeld WF; Hanifin JM; Young MR
    J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S95-102. PubMed ID: 9631991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole.
    De Doncker P; Decroix J; Piérard GE; Roelant D; Woestenborghs R; Jacqmin P; Odds F; Heremans A; Dockx P; Roseeuw D
    Arch Dermatol; 1996 Jan; 132(1):34-41. PubMed ID: 8546481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly.
    Faergemann J; Laufen H
    Acta Derm Venereol; 1996 May; 76(3):219-21. PubMed ID: 8800303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fluconazole in skin and nails.
    Faergemann J
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 2):S14-20. PubMed ID: 10367911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The uptake of fluconazole in finger and toe nails.
    Laufen H; Zimmermann T; Yeates RA; Schumacher T; Wildfeuer A
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):352-60. PubMed ID: 10442510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.
    Drake L; Babel D; Stewart DM; Rich P; Ling MR; Breneman D; Scher RK; Martin AG; Pariser DM; Pariser RJ; Ellis CN; Kang S; Katz HI; McDonald CJ; Muglia J; Savin RC; Webster G; Elewski BE; Leyden JJ; Bucko AD; Tschen EH; Hanifin JM; Morman MR; Shupack JL; Greer DL
    J Am Acad Dermatol; 1998 Jun; 38(6 Pt 2):S87-94. PubMed ID: 9631990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
    Gupta AK; Leonardi C; Stoltz RR; Pierce PF; Conetta B;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):437-43. PubMed ID: 15987289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of antifungal agents in onychomycoses.
    Debruyne D; Coquerel A
    Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
    Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
    Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study.
    Assaf RR; Elewski BE
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):216-9. PubMed ID: 8708024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
    Sigurgeirsson B; van Rossem K; Malahias S; Raterink K
    J Am Acad Dermatol; 2013 Sep; 69(3):416-25. PubMed ID: 23706639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis.
    Salo H; Pekurinen M
    Pharmacoeconomics; 2002; 20(5):319-24. PubMed ID: 11994041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison.
    Havu V; Brandt H; Heikkilä H; Hollmen A; Oksman R; Rantanen T; Saari S; Stubb S; Turjanmaa K; Piepponen T
    Br J Dermatol; 1999 Jan; 140(1):96-101. PubMed ID: 10215775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
    Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
    J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.
    Warshaw EM; Fett DD; Bloomfield HE; Grill JP; Nelson DB; Quintero V; Carver SM; Zielke GR; Lederle FA
    J Am Acad Dermatol; 2005 Oct; 53(4):578-84. PubMed ID: 16198776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis.
    Avner S; Nir N; Henri T
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1194-6. PubMed ID: 17062030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.